Brian Powl, an officer of Kura Oncology, Inc., filed a Form 144 notice on November 17, 2026, disclosing a proposed sale of 15,254 shares of common stock with an aggregate market value of $108,150.86 on NASDAQ.

Key Highlights

  • Proposed sale: Brian Powl, listed as an officer, intends to sell 15,254 shares of Kura Oncology common stock.
  • Aggregate market value: The proposed shares carry an aggregate market value of $108,150.86, according to the filing.
  • Shares outstanding: The filing reports 91,878,694 shares of common stock outstanding.
  • Source of shares: The 15,254 shares were acquired on November 13, 2026, through restricted stock units granted by the issuer.
  • 10b5-1 plan: The filing indicates a written trading plan was adopted on May 22, 2026, and prior sales were executed under that plan.
  • Prior three-month sales: Sales in the prior three months totaled shares sold on four separate dates, September 27, September 28, September 29, and August 21, 2026, with gross proceeds of $94,685.65, $84,497.60, $165,852.44, and $51,663.26, respectively.
  • Broker: Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004, is named as the broker.

Brian Powl's Proposed Rule 144 Sale at Kura Oncology

According to the Form 144 filing dated November 17, 2026, Brian Powl, an officer of Kura Oncology, Inc. (NASDAQ:KURA), filed a notice of proposed sale of securities pursuant to Rule 144 under the Securities Act of 1933. The filing discloses an intent to sell 15,254 shares of the company's common stock, with an approximate sale date of November 17, 2026, and an aggregate market value of $108,150.86.

The filing states that the 15,254 shares to be sold were acquired on November 13, 2026, through a restricted stock unit transaction from the issuer, with payment recorded on the same date. The company's address is listed as 4930 Directors Place, Suite 500, San Diego, California 92121. The total shares of common stock outstanding are reported as 91,878,694.

The filing also discloses sales of common stock during the three months preceding the notice. Those prior sales, attributed to Brian Powl or to 10b5-1 plan sales for Brian Powl, occurred on August 21, 2026 (4,345 shares, $51,663.26 gross proceeds), September 27, 2026 (9,020 shares, $94,685.65 gross proceeds), September 28, 2026 (8,000 shares, $84,497.60 gross proceeds), and September 29, 2026 (15,430 shares, $165,852.44 gross proceeds). The filing indicates the written 10b5-1 trading plan was adopted on May 22, 2026.

What Was Disclosed

Kura Oncology officer Brian Powl submitted a Form 144 notice proposing to sell 15,254 shares of common stock with an aggregate market value of $108,150.86, acquired via restricted stock units on November 13, 2026, under a 10b5-1 plan adopted May 22, 2026.